Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight

Basit Öğe Kaydı
dc.contributor.authorGul, Yahya
dc.contributor.authorKapakli, Hasan
dc.contributor.authorGuner, Sukru Nail
dc.contributor.authorAlan, Havva Bozkurt
dc.contributor.authorHazar, Esra
dc.contributor.authorKeles, Sevgi
dc.contributor.authorReisli, Ismail
dc.date.accessioned2024-02-23T13:56:15Z
dc.date.available2024-02-23T13:56:15Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractPurpose The aim was to review the compliance, side effects and effectiveness of subcutaneous immunoglobulin (SCIG) supplementation in patients with primary immunodeficiencies (PID) who had previously received intravenous immunoglobulin (IVIG) therapy and subsequently switched to SCIG, as well as to compare these parameters in patients while considering body weight. Methods Demographic data, clinical and laboratory findings, SCIG dose, and side effects of 87 patients were retrospectively obtained from patient files. In patients who first received IVIG and then SCIG, the monthly SCIG dose was calculated by multiplying the IVIG dose by 1.37. The total monthly SCIG dose was distributed via injection across three or four doses per month, thus every 7 or 10 days. Results Of the 87 patients aged between one and 22 years, 50 were male (57.5%) and 37 were female (42.5%). The serum IgG levels of the SCIG group were higher and more stable than those of the IVIG group. The number of hospitalizations and infections decreased significantly after initiation of SCIG. Thirteen patients (14.9%) had low body weight (LBW) for their age, seven of whom were male (53.8%). Serum IgG levels of the LBW cohort were significantly elevated and more stable during the SCIG period than the IVIG period. Mild, local side effects were detected in 153 administrations (3.3%) in 30 patients with normal body weight, while no local reactions were recorded in the patients with LBW. Conclusion SCIG supplementation is an effective treatment for pediatric patients with PID. The preliminary data from the present study suggest that such treatment is also safe for LBW children. The numbers of patient hospitalizations and family visits to clinics were reduced, allowing our patients and their parents to live more normal lives.en_US
dc.identifier.doi10.1007/s10875-021-01144-x
dc.identifier.endpage71en_US
dc.identifier.issn0271-9142
dc.identifier.issn1573-2592
dc.identifier.issue1en_US
dc.identifier.pmid34617265en_US
dc.identifier.scopus2-s2.0-85116598666en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage64en_US
dc.identifier.urihttps://doi.org/10.1007/s10875-021-01144-x
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11146
dc.identifier.volume42en_US
dc.identifier.wosWOS:000705822400001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer/Plenum Publishersen_US
dc.relation.ispartofJournal Of Clinical Immunologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPrimary Immunodeficiencyen_US
dc.subjectSubcutaneous Immunoglobulinen_US
dc.subjectMalnutritionen_US
dc.subjectLow Body Weighten_US
dc.titleLong-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weighten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu